Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies how well panitumumab with or without trametinib works in
treating patients with stage IV colorectal cancer. Immunotherapy with monoclonal antibodies,
such as panitumumab, may help the body's immune system attack the cancer, and may interfere
with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving panitumumab with or
without trametinib may work better in treating patients with stage IV colorectal cancer.